Mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
=== Conjugation via thiol group === Another process of creating immunoliposomes is by using a thiol group and creating a thioether bond. The sulfhydryl group is a key player can is found in cysteine bridges on proteins and reagents like Traut's reagents, SATA, and Sulfo-LC-SPDP. The reduction or hydrolysis of these groups generates thiol groups that create antibody conjugation to lipids. There are multiple methods of this process, and one uses the crosslinking agent SATA as shown in Figure 3. The ester end of SATA reacts with amino groups in proteins to form an amide link and a molecule with a protected sulfhydryl group. In order to continue the reaction, this group must be freed which is done by adding hydroxylamine. The following step is to add a chemical that can be an anchor between the lipid and the thiol group. Some examples of molecules that are capable of being this anchor are maleimide, iodoacetyl groups or 2-pyridyldithiol groups. Ultimately, these steps create an antibody-enzyme conjugate that has been formulated using a thiol group.
=== Hydrodynamic injection === For loading the analytes, the capillary is firstly placed into sample vial. Then there are different ways for hydrodynamic injection: it can be applied positive pressure to inlet, negative pressure to outlet or the sample inlet can be raised in relation to capillary outlet. This technique is able to provide robust and reproducible injected sample amount in comparison to electrokinetic injection and injection RSD value are usually below 2 %. Injected volume and reproducibility of the sample usually depends on injection time, sample height displacement and the pressure applied to the sample. For example, it has been found that using higher pressure and lower injection time leads to reducing of the RSD for peak areas and migration times. One of the main advantages of hydrodynamic injection is also that it is unbiased to molecules with high or low electrophoretic mobility. To increase throughput of CE–MS analysis hydrodynamic multisegment injection technique was created. In this case several samples are loaded hydrodynamically to the separation capillary before the analysis and each sample segment is placed between background electrolyte spacers.
AB Tetra Pak was established in Lund, Sweden, in 1951 as a subsidiary to Åkerlund & Rausing. In May of that year, the new packaging system was presented to the press, and in 1952, the first filling machine producing 100 ml cream tetrahedrons was delivered to Lundaortens Mejeriförening, a local dairy. In subsequent years, tetrahedron packages became more and more common in Swedish grocery stores, and in 1954, the first machine producing 500 ml milk packages was sold to a Stockholm dairy. That same year, the first machine was exported to Hamburg, Germany, soon to be followed by France (1954), Italy (1956), Switzerland (1957), and later the Soviet Union (1959) and Japan (1962).
Sources: en.wikipedia.org
nonsynonymous mutation Also nonsynonymous substitution or replacement mutation. A type of mutation in which the substitution of one nucleotide base for another results, after transcription and translation, in an amino acid sequence that is different from that produced by the original unmutated gene. Because nonsynonymous mutations always result in a biological change in the organism, they are often subject to strong selection pressure. Contrast synonymous mutation.
The first king of Hungary, Stephen I, who supported Western European missionaries, defeated the local chieftains and established Roman Catholic bishoprics (office of a bishop) in Transylvania and Banat in the early 11th century. Significant Pecheneg groups fled to the Byzantine Empire in the 1040s; the Oghuz Turks followed them, and the nomadic Cumans became the dominant power of the steppes in the 1060s. Cooperation between the Cumans and the Vlachs against the Byzantine Empire is well documented from the end of the 11th century. Scholars who reject the Daco-Roman continuity theory say that the first Vlach groups left their Balkan homeland for the mountain pastures of the eastern and southern Carpathians in the 11th century, establishing the Romanians' presence in the lands to the north of the Lower Danube.
Abdominal muscles cover the anterior and lateral abdominal region and meet at the anterior midline. These muscles of the anterolateral abdominal wall can be divided into four groups: the external obliques, the internal obliques, the transversus abdominis, and the rectus abdominis.
The most common symptom of a spinal CSF leak is a fast-onset, extremely painful orthostatic headache. This headache is usually made worse by standing and typically becomes prominent throughout the day, with the pain becoming less severe when lying down. Orthostatic headaches can become chronic and disabling to the point of incapacitation. Some people will develop headaches that begin in the afternoon. This is known as second-half-of-the-day headache. This may be an initial presentation of a spontaneous CSF leak or appear after treatment such as an epidural patch, and likely indicates a slow spinal CSF leak. While high CSF pressure can make lying down unbearable, low CSF pressure due to a leak can be relieved by lying flat on the back. About 50% of people with a spinal CSFL experience neck pain or stiffness, nausea, and vomiting. Other symptoms of a CSF leak include photophobia, dizziness and vertigo, gait disturbances, tinnitus, facial numbness or weakness, visual disturbances, brain fog or difficulties with concentration, neuralgia, fatigue, fluid dripping from the nose or ears. Aural symptoms are also present in many cases of intracranial hypotension due to CSF leak; including muffled hearing, pulsatile tinnitus, hearing loss. Less common symptoms include double vision (due to cranial nerve 6 palsy) or tremor. Movement disorders are uncommon in spontaneous CSF leaks but occasionally can be one of the major components of the clinical presentation.
Sources: en.wikipedia.org
== Gambia == Adama Barrow – Politician and real estate developer. Current president, Republic of the Gambia Assan Musa Camara - Former vice president, former minister of education, finance, External affairs, Gambia. Isatou Njie-Saidy – Politician. former vice president, former secretary of state Social Welfare, Health and Women's Affair, Republic of the Gambia Fatoumata Tambajang – Politician and Activist. former vice president, former Minister of Women's Affair, Republic of the Gambia Hassan Bubacar Jallow – Judge. Chief Justice of the Gambia since February 2017, former Prosecutor of the International Criminal Tribunal for Rwanda (ICTR), former Prosecutor of the Mechanism for International Criminal Tribunals, former justice of the Supreme Court of the Gambia, former Minister of Justice-Attorney General of the Gambia and former solicitor general of the Gambia. Muhammad B. S. Jallow – Vice President of the Gambia Dawda A. Jallow (In German) - Attorney general and Minister of Justice. Awa Bah (in German) - Jurist, First Female president of the Gambian Court of Appeal, Supreme court judge. Naceesay Salla-Wadda - Jurist, Second female president of the Gambian court of Appeal. Fatou Baldeh - Gambian women's rights activist, Abdoulie Cham- former Minister of Information and Communication Infrastructure. Ousman Sowe (in German) - Former DG State Intelligence Service. Abdoulie Jobe (politician)(in German) - Former Minister Of Energy and Petroleum. Ebrahim M.
== History == NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH. In 2013, the company launched its sequencing platform and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis. In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc., a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare. Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas. In November 2017, NeoGenomics established their first headquarters outside the United States in Rolle, Switzerland. In September 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay, which was preliminarily enjoined in December 2023.
=== Early puberty === CPA is used as an antiandrogen and antiestrogen to treat precocious puberty in boys and girls. However, it is not fully satisfactory for this indication because it is not able to completely suppress puberty. It does not suppress skeletal maturation enough to avoid a reduction in height at adulthood. For this reason, CPA has mostly been superseded by GnRH agonists in the treatment of precocious puberty. CPA is not satisfactory for gonadotropin-independent precocious puberty. CPA has been used at dosages of 50 to 300 mg/m2 to treat precocious puberty.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.